Based on the METX stock forecast from 0 analysts, the average analyst target price for METX is not available over the next 12 months. METX’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of METX is Neutral, which is based on 2 positive signals and 2 negative signals. At the last closing, METX’s stock price was CAD 4.30. METX’s stock price has changed by +3.61% over the past week, +10.26% over the past month and +377.78% over the last year.
No recent analyst target price found for METX
No recent average analyst rating found for METX
Company Overview METX
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company was incorporated in 2021 and is headquartered in Vancouver, Canada. Read Less
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
Frequently Asked Questions About METX (METX:CA) Stock
Stock Target Advisor's fundamental analysis for METX's stock is Neutral.
Unfortunately we do not have enough data on METX:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on METX:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on METX:CA's stock to indicate if its overvalued.
The last closing price of METX:CA's stock was CAD 4.30.
The most recent market capitalization for METX:CA is CAD 0.10B.
Unfortunately we do not have enough analyst data on METX:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains METX's stock.
As per our most recent records METX has 0 Employees.
METX's registered address is 177 Robson Street, Vancouver, BC, Canada, V6B 0N3.
You can get more information about it from METX's website at https://www.metherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Frequently Asked Questions About METX (METX:CA) Stock
Stock Target Advisor's fundamental analysis for METX's stock is Neutral.
Unfortunately we do not have enough data on METX:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on METX:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on METX:CA's stock to indicate if its overvalued.
The last closing price of METX:CA's stock was CAD 4.30.
The most recent market capitalization for METX:CA is CAD 0.10B.
Unfortunately we do not have enough analyst data on METX:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains METX's stock.
As per our most recent records METX has 0 Employees.
METX's registered address is 177 Robson Street, Vancouver, BC, Canada, V6B 0N3.
You can get more information about it from METX's website at https://www.metherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for METX:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
